An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...

Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...

Multiple molecular pathways play a role in gastric cancer development, influencing how genetic and environmental factors interact to drive tumor growth and progressiA recent study by researchers at ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, largely due to metastasis and therapeutic ...

For more details about SABCS please visit: https://www.sabcs.org/.

Human epidermal growth factor receptor 2 (HER2) is a membrane-spanning receptor that belongs to the family of epidermal growth factor receptor tyrosine kinases (EGFR TKIs), which consists of three ...